Oral Oncology 48 (2012) 636–640

Contents lists available at SciVerse ScienceDirect

Oral Oncology

journal homepage: www.elsevier.com/locate/oraloncology



DNA ploidy measurement in oral leukoplakia: Different results between flow and image cytometry

E.R.E.A. Brouns [a], E. Bloemena [a,b], J.A.M. Belien [b], M.A.M. Broeckaert [b], I.H.A. Aartman [c], I. van der Waal [a,*]

[a] VU University Medical Center (VUmc)/Academic Centre for Dentistry Amsterdam (ACTA), Department of Oral and Maxillofacial Surgery and Oral Pathology, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
[b] VU University Medical Center (VUmc), Department of Pathology, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
[c] Academic Centre for Dentistry Amsterdam (ACTA), Department of Social Dentistry and Behavioural Sciences, P.O. Box 7822, 1008 AA Amsterdam, The Netherlands

ARTICLE INFO

Article history:
Received 10 August 2011
Received in revised form 16 January 2012
Accepted 26 January 2012
Available online 18 February 2012

Keywords:
DNA ploidy
Flow cytometry
Image cytometry
Oral epithelial dysplasia
Oral leukoplakia
Oral squamous cell carcinoma
Potentially malignant disorder

SUMMARY

The estimated prevalence of oral leukoplakia is worldwide approximately 2%, with an annual malignant transformation rate of approximately 1%. The aim of the present study was to evaluate the possible contribution of ploidy measurement to the prediction of the clinical course, in a well defined cohort of patients with oral leukoplakia. Ploidy was measured by both flow cytometry (FCM-DNA) and image cytometry (ICM-DNA) and we focussed on the comparison of the two different techniques to determine ploidy. A total of 41 patients have been included, with a mean age of 59 years (range 36–78 years). With FCM-DNA, three lesions were aneuploid, with ICM-DNA, 19 lesions were aneuploid. DNA ploidy was compared with clinicopathological and patients parameters. There were no statistically significant differences between DNA ploidy and any patient factor with both FCM-DNA and ICM-DNA. Using FCM-DNA, DNA aneuploid lesions showed statistically significant more dysplasia ($p = 0.04$) than diploid lesions. Furthermore, DNA aneuploid lesions were more frequently encountered at high-risk locations ($p = 0.03$) as being determined with FCM-DNA. These relations were not found when DNA ploidy was determined with ICM-DNA.

© 2012 Elsevier Ltd. Open access under the Elsevier OA license.

Introduction

Leukoplakia is defined as 'a white plaque of questionable risk having excluded (other) known diseases or disorders that carry no increased risk for cancer'.[1] The estimated prevalence of oral leukoplakia worldwide is approximately 2%,[2] with an annual malignant transformation rate into oral squamous cell carcinoma (OSCC) of approximately 1%.[3] Several factors are known to be associated with an increased risk of malignant transformation of leukoplakia, e.g. homogeneity and size of the lesion.[3–5] At present, the best predictor is the presence of epithelial dysplasia. Nevertheless, some dysplastic lesions may remain unchanged or resolve over time.[6,7] A limitation of dysplasia grading is its relative subjective character, indicated by a high inter- and intra-examiner variability in the assessment of dysplasia.[8–11]

Another suggested parameter of prognostic value could be DNA ploidy measurement.[12] DNA aneuploid lesions in Barrett's esophagus have shown a higher risk of malignant transformation[13] and DNA aneuploid gastric cancer has an unfavourable prognosis compared to DNA diploid cancer.[14] Recent DNA ploidy studies of dysplastic oral lesions have suggested that DNA aneuploid lesions carry a higher risk for OSCC progression.[15–18] The DNA ploidy status can be measured by either flow cytometry (FCM-DNA) or image cytometry (ICM-DNA).

The aim of the present study was to evaluate the possible difference between DNA ploidy measurement using either FCM-DNA or ICM-DNA, in a well defined cohort of patients with oral leukoplakia. This study is a continuation of the study of Bremmer et al.[18] Relations between DNA ploidy and the histopathological grading and other clinical parameters, such as gender, smoking habit, alcohol consumption, homogeneity, size and location of the lesion were investigated. Moreover, all leukoplakias were classified by the OL-classification and staging system.[3]

Material and methods

Patients

For the purpose of this retrospective study, 87 patients were selected on the basis of biopsied leukoplakias with sufficient material for histopathological grading as well for DNA ploidy measurement,

* Corresponding author. Tel.: +31 20 4444039; fax: +31 20 4444046.
E-mail addresses: 5806399@ student.acta.nl (E.R.E.A. Brouns), e.bloemena@vumc.nl (E. Bloemena), jam.belien@vumc.nl (J.A.M. Belien), mam.broeckaert@vumc.nl (M.A.M. Broeckaert), i.aartman@acta.nl (I.H.A. Aartman), i.vanderwaal@vumc.nl (I. van der Waal).

1368-8375 © 2012 Elsevier Ltd. Open access under the Elsevier OA license.
doi:10.1016/j.oraloncology.2012.01.013

and a minimum follow-up time of 12 months. All patients were referred to the Department of Oral and Maxillofacial Surgery at VUmc/ACTA, Amsterdam, and the biopsies were taken between 2003 and 2010. Patients with an (previous or concomitant) OSCC were excluded ($n = 8$). Also, patients in whom DNA ploidy could not be determined were excluded ($n = 38$). A total of 41 out of 87 patients fulfilled all inclusion criteria: 20 men and 21 women, with a mean age of 59 years (range 36–78 years). Nine patients in this cohort overlapped between this study and the study by Bremmer et al.[18] The smoking habits and alcohol consumption of these patients are shown in Table 1.

Clinically, a distinction was made between homogenous and non-homogeneous leukoplakia. There were 28 patients with a homogeneous leukoplakia and 13 with the non-homogeneous type. The location of leukoplakia was specified according to six sites: tongue, floor of mouth (FOM), hard palate, buccal mucosa, upper and lower alveolus and gingiva, and multiple sites (Table 2). All this information was extracted from the patient files.

The size, presence and grade of epithelial dysplasia were determined by means of the OL-classification and staging system (Table 3).[3] Twenty-three leukoplakias were L_1, 10 cases were L_2 and seven were L_3. Size could not be determined in one case. There were 23 excisional and 18 incisional biopsies performed. All biopsies were revised on haematoxylin and eosin (H&E) stained sections by the same investigators (EREAB/EB), a joint consensus was made for the cases that were graded differently. Severe dysplasia (P_2) was diagnosed in six biopsies, mild-moderate dysplasia (P_1) in 14 biopsies, while dysplasia was absent (P_0) in 21 biopsies. The biopsy on which the histological grading was done, was also used for DNA ploidy determination.

Initial and follow-up management included surgical excision, CO_2-laser therapy or observation. All patients were advised to quit smoking.[19] The follow-up period ranged from 12 to 87 months with a median of 20 months. The follow-up period started at the date the biopsy was taken. It ended in case of lost to follow-up, death, or development of OSCC at the site of oral leukoplakia or elsewhere in the oral cavity.

The design of this study adheres to the code for proper secondary use of human tissue of the Dutch Federation of Biomedical Scientific Societies (http://www.federa.org).[20]

Tissue processing for FCM-DNA and ICM-DNA

Formalin fixed paraffin-embedded tissue specimens, the same which were used for histopathological grading, were collected from the pathology archive. Two or three 50 μm sections were cut from the tissue specimens and nuclear cell suspensions were prepared according to the Hedley procedure.[21] For FCM-DNA, part of the nuclear suspension was stained with DAPI (4′,6-diamidino-2-phenylindol, Partec Instruments, Muenster, Germany). For ICM-DNA, cytospins were prepared from the other part by centrifugation of the specimen for 15 min at 3000 rpm. The cytospins for ICM-DNA were stained using the Feulgen method according to the consensus of the European Society for Analytical Cellular Pathology,[22] with minor modifications. Cytospin preparations were placed in 5 N HCL for 30 min at 27 °C. Hereafter the cytospins were rinsed in distilled water for 5 min, stained with fresh Schiff's reagent for 45 min, and then washed in running tap water for 15 min. Last, the cytospin slides were dehydrated and cover slipped.

Table 2
Site distribution of 41 patients with leukoplakia.

Oral subsite	Number of patients
Tongue (dorsal and lateral surfaces)	10
Floor of mouth	7
Hard palate	3
Cheek mucosa	5
Upper and lower alveolus and gingiva	4
Multiple sites	12
Total	41

Measurement of FCM-DNA

The FCM-DNA measurements were done within 3 h after DAPI staining. For the measurements a Partec Pas II mercury lamp-based flow cytometer (Partec Instruments) was used. Trout erythrocytes were used as external control cells. The procedure is described in detail elsewhere.[23]

Measurement of ICM-DNA

The DNA content of stained nuclei was measured and analysed by ICM-DNA according to a published protocol.[14,24] The guidelines of the consensus report of the European Society for Analytical Cellular Pathology were followed.[22] Köhler illumination was applied, before every ICM-DNA analysis. The camera was switched on at least 15 min before every measurement to ensure standardised conditions. Images were linearly corrected for shading with two empty images, namely one illuminated and one dark-current image.[25] The resulting corrected grey values provided a measure for the local optical density. Segmentation was carried out in a fully automatic manner.[14,24] A filter was used during measurements to remove debris and aggregates.

Approximately, 1000 nuclei were measured in a fully automatic manner. Lymphocytes and fibroblasts were included as internal DNA diploid controls and were used to calibrate and scale the DNA histogram. Using classification algorithms, round dark condense objects resembling lymphocytes and ellipsoid objects resembling fibroblasts were automatically identified. The majority of remaining debris and aggregates were automatically removed with another set of classification algorithms from the data set. The resulting DNA histograms were visually inspected. Nuclei, which should have been removed on the basis of features such as shape and texture automatically, but were missed by the classification algorithms, were removed manually.

In DNA cytometry, nuclear DNA content is measured in relative units 'c', in which the DNA content of normal nuclei is set at 2c. In this study, the 2c reference value was determined by taking the mean DNA content measured for nuclei that were identified as lymphocytes and fibroblasts. After establishing the 2c reference value, the histogram was scaled up to 10c with a fixed number of 256 bins to obtain standardised histograms that cover a wide

Table 1
Distribution of tobacco and alcohol habits among 41 patients with oral leukoplakia.

Gender	Patients	Tobacco			Alcohol		
		Smoker	Non-smoker	Unknown	Use	No-use	Unknown
Men	20	12	6	2	10	4	6
Women	21	14	5	2	6	4	11
Total	41	26	11	4	16	8	17

Table 3
Classification and staging system for oral leukoplakias (OL-system).

L (size of the leukoplakia)	
L_1	Size of single or multiple leukoplakias together <2 cm
L_2	Size of single or multiple leukoplakias together 2–4 cm
L_3	Size of single or multiple leukoplakias together >4 cm
L_x	Size not specified
P (pathology)	
P_0	No epithelial dysplasia (includes "no or perhaps mild epithelial dysplasia")
P_1	Mild or moderate epithelial dysplasia
P_2	Severe epithelial dysplasia
P_x	Absence or presence of epithelial dysplasia not specified in the pathology report
OL-staging system	
Stage 1	L_1P_0
Stage 2	L_2P_0
Stage 3	L_3P_0 or $L_1L_2P_1$
Stage 4	L_3P_1 or LP_2

General rules of the OL-staging system
1. If there is doubt concerning the correct L category to which a particular case should be allotted, than the lower (i.e. less advanced) category should be chosen. This will also be reflected in the stage grouping
2. In case of multiple biopsies of single leukoplakia or biopsies taken from multiple leukoplakias the highest pathological score of the various biopsies should be used
3. For reporting purposes the oral subsite according to the ICD-DA should be mentioned (World Health Organisation, International Classification of Diseases. Tenth Revision. Application to Dentistry and Stomatology, ICD-DA, Geneva, 1992)

range of c values that potentially occur in populations of tumour nuclei.[14]

Analysis of DNA histogram FCM-DNA and ICM-DNA

The DNA histograms were analysed using the MultiCycle AV computer programme (Phoenix Flow Systems, San Diego, CA, USA), according to a previously described protocol.[26] The DNA index was calculated by dividing the modal channel number of DNA aneuploid peaks by the corresponding number of the DNA diploid peak. In case of only one cell cycle, the DNA index was set at 1.00. All FCM-DNA and ICM-DNA cases were classified in two subclasses, based on previous published guidelines as follows[22]: DNA diploid (only one cell cycle present) and DNA aneuploid (DNA index $\geqslant$ 1.1).

Statistical analysis

Minimum, maximum, mean, and median values of continuous variables were calculated. Relevant data were cross-tabulated. Statistically significant relations were tested with the Chi-square test. The variables age, gender, smoking habit, alcohol consumption, homogeneity, dysplasia, size of the lesion, location and DNA ploidy were used. The results were statistically significant if the *P*-value was less than 0.05. For all statistical analyses, SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA) was used.

Results

Ploidy measurement by flow (FCM-DNA) and image cytometry (ICM-DNA)

In this study, 38 leukoplakias were DNA diploid and three were DNA aneuploid using FCM-DNA. However, by ICM-DNA, 19 leukoplakias were found to be DNA aneuploid (n.s.) (Table 4). Concordance between FCM-DNA and ICM-DNA was present in two lesions which were DNA aneuploid with both methods. However, one lesion was DNA aneuploid using FCM-DNA, but DNA diploid with ICM-DNA. Seventeen lesions that were DNA diploid by FCM-DNA measurement were DNA aneuploid using ICM-DNA.

Relation between clinicopathological parameters and ploidy measured by flow cytometry (FCM-DNA)

All DNA aneuploid lesions ($n = 3$) showed mild-moderate epithelial dysplasia (P_1). In total, 18% of the dysplastic leukoplakias and 7% of the whole patient group were DNA aneuploid using FCM-DNA. In contrast to DNA diploid lesions, DNA aneuploid lesions always showed dysplasia ($p = 0.04$) (Table 5). The DNA aneuploid leukoplakias were located at the FOM ($n = 2$) and lateral tongue ($n = 1$). When the location of the lesions was divided between high-risk (FOM and tongue) versus low-risk (remaining), DNA aneuploid lesions occurred statistically significantly more often at the high-risk locations ($p = 0.03$). All DNA aneuploid lesions were homogeneous. Two patients with DNA aneuploid lesions were smoker, one was a non-smoker. Two lesions were small (L_1), while one lesion was L_2. The DNA aneuploid leukoplakia in the non-smoker was homogeneous, L_1 and located at the lateral tongue. There were no statistically significant differences between DNA aneuploid and DNA diploid lesions with regard to gender ($p = 0.52$), smoking habit ($p = 0.83$) and alcohol consumption ($p = 0.52$), homogeneity ($p = 0.22$), size ($p = 0.85$) or type of biopsy ($p = 0.70$).

Relation between clinicopathological parameters and ploidy measured by image cytometry (ICM-DNA)

Of the DNA aneuploid lesions as determined by ICM-DNA ($n = 19$) eight showed no dysplasia (P_0), six were P_1 and five were P_2 (Table 5). In total, 55% of the dysplastic leukoplakias and 46% of the whole patient group were DNA aneuploid using ICM-DNA. Although there was no statistically significant difference in dysplasia between DNA diploid and DNA aneuploid lesions ($p = 0.14$), there was a trend of more severe dysplasia in DNA aneuploid lesions (Table 5). There were no statistically significant differences between DNA aneuploid and DNA diploid lesions with regard to gender ($p = 0.68$), smoking habit ($p = 0.32$) and alcohol consumption ($p = 0.47$), homogeneity ($p = 0.49$), location ($p = 0.26$), size ($p = 0.57$) or type of biopsy ($p = 0.68$).

Relation between clinicopathological parameters and dysplasia

In this study, 20/41 (50%) leukoplakias showed epithelial dysplasia, of which six cases showed severe dysplasia (P_2) (Table 5). Dysplasia (both P_1 and P_2) in leukoplakia was more often observed at the high-risk sites (tongue and FOM) than in low-risk sites ($p = 0.02$). There was no relation between dysplasia and gender ($p = 0.61$), age ($p = 0.75$), smoking habit ($p = 0.61$), alcohol consumption ($p = 0.44$), homogeneity ($p = 0.08$), or size of the lesion ($p = 0.75$).

Table 4
DNA ploidy in leukoplakia using two different methods.

FCM-DNA	ICM-DNA		Total
	Aneuploid	Diploid	
Aneuploid	2	1	3
Diploid	17	21	38
Total	19	22	41

FCM-DNA = flowcytometry.
ICM-DNA = image cytometry.

Table 5
Histopathological grading and DNA ploidy in 41 patients with oral leukoplakia.

		FCM-DNA		ICM-DNA	
		Diploid	Aneuploid	Diploid	Aneuploid
Dysplasia	P_0	21	0	13	8
	P_1	11	3	8	6
	P_2	6	0	1	5

Malignant transformation

In two out of 41 patients, two males, an OSCC developed in the leukoplakia during follow-up. The age of the patients at the time of OSCC diagnosis was 59 and 67 years, respectively. Both were smokers and only one of them used regular alcohol. Malignant transformation occurred 9 and 77 months after the initial biopsy was taken. The annual malignant transformation rate in this study is 0.6%. Both patients had multiple sites of leukoplakia. Leukoplakia was small (L_1) in one and large (L_3) in the other. The small lesion was severely dysplastic (P_2), while the large lesion was non dysplastic (P_0). Both leukoplakias were DNA diploid in FCM-DNA, but DNA aneuploid using ICM-DNA (DNA-index 1.24 and 1.32). The number of patients with malignant transformation in this cohort is too small and the length of follow-up may have been too short to allow statistical analysis.

Discussion and conclusions

In the present study, 41 patients with oral leukoplakia and ploidy determination were included in the period between 2003 and 2010. There have been much more patients with an oral leukoplakia observed in this period, but not always a biopsy was taken.

It is questionable whether the histopathological findings in an incisional biopsy from a leukoplakia are representative of the entire lesion[27]; possibly, this also applies for the DNA ploidy measurement.

There is a big difference in the number of DNA aneuploid lesions as being determined with different techniques, viz. FCM-DNA and ICM-DNA. This may be explained by the use of different preparation techniques.[14] Another explanation might be that DNA aneuploid peaks detected by ICM-DNA are not seen in FCM-DNA when the number of aneuploid epithelial cells is only small or when large numbers of stromal and inflammatory cells are present.[14] On the other hand, there was one case of DNA aneuploidy assessed with FCM-DNA, which was DNA diploid with ICM-DNA. Possibly, false positive aneuploid lesions detected by FCM-DNA may be the result of clustering nuclei, unlike ICM-DNA, in which technique this clustering is excluded during the visual inspection.[14]

In the present study, statistically significant relations were found between DNA aneuploidy determined with FCM-DNA and dysplasia. DNA aneuploid lesions assessed with FCM-DNA, occurred statistically significantly more often at high-risk locations. The latter finding is in agreement with another recent study.[28] There were no statistically significant outcomes with DNA ploidy, determined with both FCM-DNA and ICM-DNA, and any patient factor. In contrast, another recent study observed that the mean percentage of DNA aneuploid nuclei was statistically significant higher in smoking than in non-smoking patients habits.[29]

In the literature, the prevalence of DNA aneuploidy in non dysplastic and dysplastic lesions varies.[16–18,30–32] This can be due to the use of different sources of material, e.g. fresh frozen versus paraffin embedded tissue, different methods to prepare cytospins and different ways to interpret the DNA histograms. Moreover, in some studies only dysplastic lesions have been examined.

It should be noted that in the present study, both leukoplakias that progressed to an OSCC were DNA diploid with FCM-DNA, but DNA aneuploid with ICM-DNA, suggesting that the use of image cytometry is a more sensitive and clinically relevant parameter than using flow cytometry. Unfortunately however, there were not enough patients with progression to cancer to determine the possible relation between DNA ploidy (FCM-DNA and ICM-DNA) and malignant transformation. Although the exact role of DNA aneuploidy with regard to malignant transformation is still unknown, DNA aneuploidy should still be considered as a marker for malignancy.[12–17]

Conflict of interest statement

None declared.

References

1. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. *J Oral Pathol Med* 2007;**36**(10):575–80.
2. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. *Oral Oncol* 2003;**39**(8):770–80.
3. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. *Oral Oncol* 2009;**45**(4–5):317–23.
4. Dietrich T, Reichart PA, Scheifele C. Clinical risk factors of oral leukoplakia in a representative sample of the US population. *Oral Oncol* 2004;**40**(2):158–63.
5. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. *Oral Oncol* 2006;**42**(5):461–74.
6. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. *J Oral Pathol Med* 2008;**37**(1):1–10.
7. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. *Crit Rev Oral Biol Med* 2003;**14**(1):47–62.
8. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. *J Oral Pathol Med* 2008;**37**(3):127–33.
9. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1995;**80**(2):188–91.
10. Brennan M, Migliorati CA, Lockhart PB, Wray D, Al-Hashimi I, Axell T, et al. Management of oral epithelial dysplasia: a review. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007;**103 Suppl.**:S19–2.
11. Fleskens SAJH, Bergshoeff VE, Voogd AC, van Velthuysen ML, Bot FJ, Speel EJ, et al. Interobserver variability of laryngeal mucosal premalignant lesions: a histopathological evaluation. *Mod Pathol* 2011;**24**(7):892–8.
12. Sen S. Aneuploidy and cancer. *Curr Opin Oncol* 2000;**12**(1):82–8.
13. Fang M, Lew E, Klein M, Sebo T, Su Y, Goyal R. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues. *Am J Gastroenterol* 2004;**99**(10):1887–94.
14. Belien JAM, Buffart TE, Gill AJ, Broeckaert MAM, Quirke P, Meijer GA, et al. Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival. *Br J Cancer* 2009;**101**(6):1011–8.
15. Bradley G, Odell EW, Raphael S, Ho J, Le LW, Benchimol S, et al. Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. *Br J Cancer* 2010;**103**(9):1432–42.
16. Torres-Rendon A, Stewart R, Craig GT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. *Oral Oncol* 2009;**45**(6):468–73.
17. Pentenero M, Giaretti W, Navone R, Demurtas A, Rostan I, Bertolusso G, et al. DNA aneuploidy and dysplasia in oral potentially malignant disorders: association with cigarette smoking and site. *Oral Oncol* 2009;**45**(10):887–90.
18. Bremmer JF, Brakenhoff RH, Broeckaert MAM, Belien JAM, Leemans CR, Bloemena E, et al. Prognostic value of DNA ploidy status in patients with oral leukoplakia. *Oral Oncol* 2011;**47**(10):956–60.
19. Allard RHB. The practice guideline 'Treatment of tobacco addiction'. *Ned Tijdschr Tandheelkd* 2005;**112**(6):216–24.
20. Oosterhuis JW, Coebergh JW, van Veen EB. Tumour banks: well-guarded treasures in the interest of patients. *Nat Rev Cancer* 2003;**3**(1):73–7.
21. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. *J Histochem Cytochem* 1983;**31**(11):1333–5.
22. Haroske G, Baak JP, Danielsen H, Giroud F, Gschwendtner A, Oberholzer M, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. *Anal Cell Pathol* 2001;**23**(2):89–95.
23. Bergers E, van Diest PJ, Baak JP. Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. *J Clin Pathol* 1996;**49**(11):931–7.

24. Rijken AM, Belien JA, van Gulik TM, Polak MM, Offerhaus GJ, Gouma DJ, et al. DNA quantitation of distal bile duct carcinoma measured by image and flow cytometry. *Anal Quant Cytol Histol* 1999;**21**(4):303–10.
25. ten Kate TK, Belien JA, Smeulders AW, Baak JP. Method for counting mitoses by image processing in Feulgen stained breast cancer sections. *Cytometry* 1993;**14**(3):241–50.
26. Bergers E, van Diest PJ, Baak JP. Reproducibility of semi-automated cell cycle analysis of flow cytometric DNA-histograms of fresh breast cancer material. *Anal Cell Pathol* 1995;**8**(1):1–13.
27. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Oral premalignant lesions: is a biopsy reliable? *J Oral Pathol Med* 2007;**36**(5):262–6.
28. Islam MN, Kornberg L, Veenker E, Cohen DM, Bhattacharyya I. Anatomic site based ploidy analysis of oral premalignant lesions. *Head Neck Pathol* 2010;**4**(1):10–4.
29. Souto GR, Caliari MV, Lins CEC, de Aguiar MCF, de Abreu MHNG, Mesquita RA. Tobacco use increase the number of aneuploid nuclei in the clinically healthy oral epithelium. *J Oral Pathol Med* 2010;**39**(8):605–10.
30. Seoane J, Bascones A, Asenjo JA, Garcia-Pola M, Varela-Centelles PI. Flow cytometric analysis of nuclear DNA content in oral leukoplakia. *Clin Otolaryngol Allied Sci* 1998;**23**(2):136–40.
31. Donadini A, Maffei M, Cavallero A, Pentenero M, Malacarne D, Di Nallo E, et al. Oral cancer genesis and progression: DNA near-diploid aneuploidization and endoreduplication by high resolution flow cytometry. *Cell Oncol* 2010;**32**(5-):373–83.
32. Saito T, Notani K, Miura H, Fukuda H, Mizuno S, Shindoh M, et al. DNA analysis of oral leukoplakia by flow cytometry. *Int J Oral Maxillofac Surg* 1991;**20**(5):259–63.